Press Releases

March 7, 2017
Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results Read More
March 2, 2017
Protagonist Therapeutics to Present at the Barclays Global Healthcare Conference Read More
February 17, 2017
Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidates at European Crohn's and Colitis Organization (ECCO) Congress Read More
February 1, 2017
Protagonist Therapeutics to Participate in the Leerink Partners 6th Annual Global Healthcare Conference Read More
January 17, 2017
Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis Read More
January 5, 2017
Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100 Read More
November 14, 2016
Protagonist Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Read More
October 13, 2016
Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna Read More
August 10, 2016
Protagonist Therapeutics Announces Pricing of Initial Public Offering Read More
July 28, 2016
Protagonist Therapeutics Receives SBIR Funding for the Development of Injectable Hepcidin Mimetics for Treatment of Iron Overload Disorders Read More
July 8, 2016
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board Read More
May 17, 2016
Protagonist Therapeutics to Present New Data for PTG-100 and PTG-200 at Digestive Disease Week 2016 Read More
February 17, 2016
Protagonist Therapeutics Names Thomas P. O'Neil Chief Financial Officer Read More
January 8, 2016
Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100 Read More
October 20, 2015
Two Poster Presentations on Oral Peptides by Protagonist Therapeutics Accepted for the Upcoming 2015 Advances in IBD – Crohn’s & Colitis Foundation’s Clinical & Research Conference Read More
September 23, 2015
Protagonist Therapeutics Receives SBIR Funding for Oral IL-23 Receptor Antagonists for Treatment of Inflammatory Bowel Diseases Read More
September 10, 2015
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer Read More
July 16, 2015
Protagonist Therapeutics Raises $40 Million Series C Financing to Advance Oral Peptide Drugs into Clinical Development Read More
December 18, 2014
Protagonist Therapeutics Names William A. Hodder as Senior Vice President, Corporate Development Read More
December 4, 2014
Protagonist Therapeutics Closes 2nd Tranche of $18 Million Series B for Advancing Development Candidate to Clinical Trials in 2015 Read More